METI adds pharmaceutical and special medical device manufacturing businesses to core designated business sectors subject to inward direct investment screening.
On June 15, 2020, the government of Japan publicized the public notices of revision in an official gazette concerning the addition of manufacturing business involving pharmaceuticals for specific infectious diseases manufacturers as well as specially-controlled medical devices manufacturers to the core designated business sectors subject to inward direct investment screening.
In light of recent expansion of the novel coronavirus disease, the government considers it important to maintain the base of domestic medical manufacturing industries which are significant to public health and to appropriately prevent situations that may cause serious impacts on national security and health. From these viewpoints, the government decided to take necessary measures, and include the addition of:
- Manufacturing businesses involving pharmaceuticals for specific infectious disease (including the intermediate of such pharmaceuticals); and
- Manufacturing businesses involving specifically-controlled medical devices (including accessories and parts thereof);
to the core designated businesses sectors, which are subject to prior-notification requirement under the Foreign Exchange and Foreign Trade Act (Act No. 228 of 1949) and, on June 15, 2020, the government publicized the related public notices of the revision* in the official gazette.
The provisions in the public notices of the revised core/designated business sectors hereby publicized will be applied to inward direct investment, etc. undertaken on or after July 15, 2020, the date after the grace period of 30 days.
To continue reading this article please go to METI .